Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital gives an overview of the upcoming treatment trends for genitourinary cancers…
Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital discusses his presentation, “Orphan Cancers with Opportunities for Improved Treatment (ARS)”…
Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital gives an overview of his presentation “Orphan Cancers with Opportunities for…
James Brugarolas, MD of UT Southwestern Medical Center gives an overview of the new kidney cancer research that was presented…
James Brugarolas, MD of UT Southwestern Medical Center discusses the use of targeted therapies in treating non-clear cell renal cell…
Freddie C. Hamdy, MD of University of Oxford gives an overview of the new research that was discussed regarding prostate…
Freddie C. Hamdy, MD of University of Oxford gives his take on which choice would warrant over the others when…
Freddie C. Hamdy, MD of University of Oxford discusses the how surgery, radiation, and active surveillance arms of the ProtecT…
Freddie C. Hamdy, MD of University of Oxford discusses the results of the ProtecT study, which was presented at the…
Freddie C. Hamdy, MD of University of Oxford gives an overview of how the ProtecT study was designed for prostate…
Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses how immunotherapies are being integrated into treatment for…
Eric Jonasch, MD of MD Anderson Cancer Center gives an overview of how targeted therapies are being used in treating…
Eric Jonasch, MD of MD Anderson Cancer Center discusses what approaches should physicians consider when treating patients with metastatic non-clear…
Eric Jonasch, MD of MD Anderson Cancer Center discusses the use of adjuvant therapy to treat patients with non-metastatic renal…
James Brugarolas, MD of UT Southwestern Medical Center gives his take on which non-metastatic renal cell cancer patients should receive…
In this presentation from Lymphoma & Myeloma 2016, Dr. Steven Coutre provides an update on approved tyrosine-kinase inhibitors (TKIs) and…
In this presentation from Lymphoma & Myeloma 2016, Dr. Richard R. Furman discusses the recent FDA approval of venetoclax for…
In this presentation from Lymphoma & Myeloma 2016, Dr. Bruce D. Cheson discusses the role of chemotherapy in the management…
In this presentation from Lymphoma & Myeloma 2016, Dr. Susan Slager discusses the epidemiology of chronic lymphocytic leukemia (CLL), and…
In this presentation from Lymphoma & Myeloma 2016, Dr. Y. Lynn Wang discusses ibrutinib resistance-mechanisms in the treatment of chronic…
In this presentation from Lymphoma & Myeloma 2016, Dr. Jennifer R. Brown discusses the BCR signaling pathway in the treatment…
In this presentation from Lymphoma & Myeloma 2016, Dr. Paul G. Richardson examines how to make sense of the many…
In this presentation from Lymphoma & Myeloma 2016, Dr. Tomer M. Mark discusses monoclonal antibodies in the therapeutic treatment of…
In this presentation from Lymphoma & Myeloma 2016, Dr. Adriana C. Rossi discusses whether second- and third-line agents should be…
This Key Insights activity features conference chair Kathy S. Albain and Dr. Eric P. Winer discussing highlights from the 14th…
David J. McConkey, PhD of Johns Hopkins Greenberg Bladder Cancer Institute gives his take on what specific drugs have potential…
David J. McConkey, PhD of Johns Hopkins Greensberg Bladder Cancer Institute gives his opinion on what physicians need to know…
David J. McConkey, PhD of Johns Hopkins Greensberg Bladder Cancer Institute discusses whether or not non-invasive imaging will be ready…
David J. McConkey of Johns Hopkins Greensberg Bladder Cancer Institute explains why some bladder cancer subtypes respond to immunotherapy and…
David J. McConkey, PhD of Johns Hopkins Greensberg Bladder Cancer Institute discusses genomics and how they change treatment for bladder…
David J. McConkey, PhD of Johns Hopkins Greenberg Bladder Cancer Institute discusses how genomics help our understanding of heterogeneity in…
Ana Aparicio, MD of MD Anderson Cancer Center discusses her opinion on whether or not BRCA1 and BRCA2 genetic testing…
Ian Tannock, MD, PhD, DSc, from the University of Toronto, Toronto, Canada, discusses the problems limiting the use of personalized…
Paolo Ascierto, MD, of the National Tumor Institute Fondazione G. Pascale, Naples, Italy, introduces the SECOMBIT Phase II trial (NCT02631447)…
Matti Aapro, MD, from the Clinique de Genolier, Genolier, Switzerland, discusses initiatives such as All.Can, which aim to improve the…
Markus Hartmann, PhD, from European Consulting & Contracting in Oncology, Trier, Germany, discusses reasons for divergent outcomes of health technology…
Laurence Albiges, MD, PhD, from the Gustave Roussy Institute, Villejuif, France discusses the safety of cabozantinib treatment in metastatic renal…
Ian Tannock, MD, PhD, DSc, from the University of Toronto, Toronto, Canada, gives advice on presenting research at the European…
Francesco Florindi from the European Cancer Patient Coalition introduces new recommendations on fostering collaboration between cancer patient organizations and hospitals,…
Paolo Ascierto, MD, of the National Tumor Institute Fondazione G. Pascale, Naples, Italy, gives an overview of the use of…
Matti Aapro, MD, from the Clinique de Genolier, Genolier, Switzerland discusses research on the benefits of pegfilgrastim over filgrastim in…
Markus Hartmann, PhD, from European Consulting & Contracting in Oncology, Trier, Germany, discusses his talk on divergent outcomes of health…
Laurence Albiges, MD, PhD, from the Gustave Roussy Institute, Villejuif, France discusses data on the efficacy of targeted therapies after…
Minh-Ha Tran, DO, Associate Medical Director, Transfusion Medicine, Pathology School of Medicine discusses Adhesion molecules and the role of Rivipansel…
Minh-Ha Tran, DO, Associate Medical Director, Transfusion Medicine, Pathology School of Medicine discusses Daratumumab could result in false positive reactivity…
Deepa Jeyakumar, MD, Assistant Clinical Professor, Division of Hematology/Oncology, UC Irvine Health discusses New Clinical Impacts on AML for 2017…
Deepa Jeyakumar, MD, Assistant Clinical Professor, Division of Hematology/Oncology, UC Irvine Health discusses AML Highlights from ASH 2016 at MOASC…
Lauren C. Pinter-Brown MD, FACP, Health Sciences Professor of Medicine and Dermatology, Chao Family Comprehensive Cancer Center, UC-Irvine discusses the…
Lauren C. Pinter-Brown MD, FACP, Health Sciences Professor of Medicine and Dermatology, Chao Family Comprehensive Cancer Center, UC-Irvine discusses practice…
Lauren C. Pinter-Brown MD, FACP, Health Sciences Professor of Medicine and Dermatology, Chao Family Comprehensive Cancer Center, UC-Irvine compares Obinutuzumab…
Gordon D. McLaren, M.D., University of California, Irvine, Irvine, CA, VA Long Beach Healthcare System, Long Beach, CA discusses how…
Gordon D. McLaren, M.D., University of California, Irvine, Irvine, CA, VA Long Beach Healthcare System, Long Beach, CA discusses the…
Gordon D. McLaren, M.D., University of California, Irvine, Irvine, CA, VA Long Beach Healthcare System, Long Beach, CA discusses the…
Yasir Khan, MD, UC Irvine Health outlines how early studies show that DOACS may be promising in VTE at the…
Yasir Khan, MD, UC Irvine Health, compares Low Molecular Weight Heparin vs. DOACS in the management of DVT and VTE…
Yasir Khan, MD, UC Irvine Health, outlines how DOACS studies may be practice changing for VTE at the MOASC Spotlight…
Angela Fleischman MD PhD, UC Irvine Health discusses how a Trametinib Early Study Shows Impressive Results for MPN at MOASC…
Angela Fleischman MD PhD, UC Irvine Health outlines the real world changes in MPN for 2017 at the MOASC Spotlight…
Angela Fleischman MD PhD, UC Irvine Health discusses the new developments in MPN for 2017 at the MOASC Spotlight on…
Aditi Choudhry, MD, Hematology Oncology Fellow UC Irvine discusses how Ibrutinib May Replace Chemotherapy in CLL at MOASC Spotlight on…
Aditi Choudhry, MD, Hematology Oncology Fellow UC Irvine discusses the 5 Year Experience With Ibrutinib in CLL at the MOASC…
Elizabeth Brém, MD, HS Clinical Assistant, Professor Chao Comprehensive Cancer Center discusses the Future of Relapse Refractory Treatment in Hodgkins…
Elizabeth Brém, MD, HS Clinical Assistant Professor, Chao Comprehensive Cancer Center discussing Incorporating immunotherapy in Hodgkins Lymphoma at the MOASC…
Elizabeth Brém, MD, HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Using PET Scan for Early Stage Hodgkin Lymphoma…
Ana Aparicio, MD of MD Anderson Cancer Center discusses her presentation “Advances in the Understanding and Treatment of AR-Indifferent Disease,”…
Ana Aparicio, MD of MD Anderson Cancer Center gives her perspective on how to sequence commonly used agents in prostate…
Ana Aparicio, MD of MD Anderson Cancer Center gives her take on whether immunotherapy will be added to treatment guidelines…
Ana Aparicio, MD of MD Anderson Cancer Center discusses how the CHARTED and STAMPEDE trials impacted her treatment for patients…
Ana Aparicio, MD of MD Anderson Cancer Center discusses how and where does chemotherapy fit for treating patients with prostate…
Ana Aparicio, MD of MD Anderson Cancer Center gives her take on which prostate cancer patients should be treated with…
Aly-Khan Lalani, MD of Dana Farber Cancer Institute gives an overview of his poster presentation about proton pump inhibitors in…
Aly-Khan Lalani, MD of Dana Farber Cancer Institute gives his thoughts on the use of immunotherapy to treat patients with…
Aly-Khan Lalani, MD of Dana Farber Cancer Institute discusses the integration of immunotherapies into renal cell carcinoma at the 2017…
Aly-Khan Lalani, MD of Dana Farber Cancer Institute gives an overview of the research he found most interesting, which were…
Alexandra Drakaki, MD, PhD of University of California, Los Angeles gives an overview of the highlights in Bladder Cancer research…
Alexandra Drakaki, MD, PhD of University of California, Los Angeles discusses what physicians need to know about the progress that’s…
Alexandra Drakaki, MD, PhD of University of California, Los Angeles discusses the role of microRNA in Bladder Cancer and its…
Georgina Long, MD, PhD, from the University of Sydney, Sydney, Australia, gives an overview of her talk on neoadjuvant therapy…
Martin Gore, PhD, FRCP, CBE from the Royal Marsden NHS Foundation, London, UK discusses why inefficiency in cancer care should…
Rodabe N. Amaria, MD from the University of Texas MD Anderson Cancer Center, Houston, TX gives an overview on the…
Susan OBrien, M.D., UC Irvine Health outlines how small molecule combinations may some day supplant chemotherapy in CLL at MOASC…
Susan OBrien, M.D., UC Irvine Health gives an Update on Resonate 2 Trial and presents new Venetoclax data at MOASC…
Susan OBrien, M.D., UC Irvine Health discusses how new Ibrutinib data may change current practices in CLL from MOASC Spotlight…
Minh-Ha Tran, DO, Associate Medical Director, Transfusion Medicine, Pathology School of Medicine presents an updates in transfusion medicine at the…
Lauren C. Pinter-Brown MD, FACP, Health Sciences Professor of Medicine and Dermatology, Chao Family Comprehensive Cancer Center, UC-Irvine discusses new…
Susan OBrien, M.D., UC Irvine Health gives a comprehensive overview and update on CLL for 2017 at MOASC Spotlight on…
Gordon D. McLaren, M.D., University of California, Irvine, Irvine, CA, VA Long Beach Healthcare System, Long Beach, CA discusses Hereditary…
Deepa Jeyakumar, MD, Assistant Clinical Professor, Division of Hematology/Oncology, UC Irvine Health gives an overview of new data and research…
Jana Pelouchova from the European Cancer Patient Coalition, Brussels, Belgium discusses the challenges faced by caregivers, which she presented at…
Gabe Sonke, MD, PhD, from the Netherlands Cancer Institute, Amsterdam, Netherlands, discusses results from the Phase III MONALEESA-2 trial on…
Dirk Schadendorf, MD, PhD, from the University Hospital Essen, Essen, Germany, discusses developments in melanoma treatment at the European Cancer…
Angela Fleischman MD PhD, UC Irvine Health gives an update on the New Developments in MPN from MOASC Spotlight on…
Martine Piccart, MD, PhD, from the Free University of Brussels, Brussels, Belgium, describes the AURORA program (NCT02102165), which seeks to…
Werner Lichtenegger, MD, PhD from Charité University Hospital, Berlin, Germany, highlights innovations in gynecological cancer treatment at the European Cancer…
Rodabe N. Amaria, MD from the University of Texas MD Anderson Cancer Center, Houston, TX summarizes results on a recent…
Aditi Choudhry, MD Hematology Oncology Fellow UC Irvine presents the Five-Year Experience With Single-Agent Ibrutinib in Patients With Previously Untreated…
Martine Piccart, MD, PhD, from the Free University of Brussels, Brussels, Belgium, describes the MINDACT trial in patients with early…
Yasir Khan, MD and Yu Cheng, MD of the University of California, Irvine, Hematology/Oncology Fellowship present Common Consults with regards…
Jana Pelouchova from the European Cancer Patient Coalition, Brussels, Belgium discusses a panel debate on informed patients at the European…
Helena Ullgren, RN at the Karolinska University Hospital, Stockholm, Sweden, discusses her talk on the gold standard for effective care…
Gabe Sonke, MD, PhD, from the Netherlands Cancer Institute, Amsterdam, Netherlands, discusses his research on the late side effects of…
Dirk Schadendorf, MD, PhD, from the University Hospital Essen, Essen, Germany, discusses the risks and benefits of adjuvant ipilimumab treatment…
Elizabeth Brém, MD, HS Clinical Assistant Professor, Chao Comprehensive Cancer Center presents Updates and Ongoing Controversies in Hodgkin Lymphoma at…
Dr. Shirish Gadgeel of the Karmanos Cancer Institute at Wayne State University in Detroit, presented new analysis results in specific…
Gerhad Mostbeck, MD of the Otto Wagner Hospital, Vienna, Austria talks about how the aims of radiology in patients with…
Shirish Gadgeel, MD, from Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, provides us with updated information on…
Frank Griesinger, MD, PhD from the Pius-Hospital Oldenburg, Oldenburg, Germany discusses the question of central nervous system (CNS) metastasis in…
Shirish Gadgeel, MD of Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI discusses driver genetic alterations, which can…
Alex Spira, MD, PhD, FACP of Virginia Cancer Specialists, Fairfax, VA discusses side effects of immunotherapy in lung cancer. Dr…
Shirish Gadgeel, MD of Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI gives an overview of his presentation…
Stefania Vallone, Lung Cancer Europe (LuCe) talks about the challenges facing lung cancer patients. LuCE conducted a survey asking lung…
Robert Pirker, MD at the Medical University of Vienna, Austria and President of the World Conference on Lung Cancer (WCLC16)…
Nicolas Girard, MD, PhD, of Hospital Louis Pradel, Claude Bernard University, Lyon, France, discusses how to maximize clinical benefits for…
Gerhad Mostbeck, MD of the Otto Wagner Hospital, Vienna, Austria talks about the challenges associated with biopsies for the diagnosis…
Frank Griesinger, MD, PhD from the Pius-Hospital Oldenburg, Oldenburg, Germany discusses progress in the development of a German clinical research…
Anne Ireland, MSN,RN, AOCN, CENP of the City of Hope National Medical Centre, Duarte, CA is interested in the adoption…
Alex Spira, MD, PhD, FACP of Virginia Cancer Specialists, Fairfax, VA talks about immunotherapies and the new challenges they present…
Sergei Grando, MD, PhD of University of California, Irvine School of Medicine, Irvine, CA talks about the popularity of e-cigarettes…
Maurice Pe?rol, MD, Léon-Bérard Cancer Centre, Lyon, France talks about angiogenesis inhibition in lung cancer across treatment lines. VEGF pathway…
Martina Pötschke-Langer, MD, from the German Cancer Research Center, Heidelberg, Germany, discusses strategies to improve tobacco control in central European…
Yu Shyr, PhD of Vanderbilt University School of Medicine, Nashville, TN discusses drug development in lung cancer and a need…
Sergei Grando, MD, PhD of University of California, Irvine School of Medicine, Irvine, CA discusses the role of nicotine in…
Sanjay Agrawal, MBBS of University Hospitals of Leicester NHS Trust, UK discusses e-cigarettes compared to smoking. 85% of lung cancer…
Rosalyn Juergens, MD, PhD of McMaster University, Juravinski Cancer Centre, Canada gives an overview of her presentation of the data…
Matthias Guckenberger, MD of University Hospital Zurich, Switzerland discusses his talk on Stereotactic Body Radiotherapy (SBRT) at the 2016 World…
Mary Duffy, RSCN, RGN, RSM of the Peter MacCallum Cancer Centre, Victoria, Australia talks about the International Thoracic Oncology Nursing…
Johan Vansteenkiste, MD, PhD of University Hospitals Leuven, Belgium talks about how patients with squamous cell carcinoma of the lung…
Lung Cancer Patient/Activist Janet Freeman-Daily talks about the successes of targeted therapies and immunotherapies in lung cancer. From a personal…
Hossein Borghaei, DO, MS of Fox Chase Cancer Center, Philadelphia, PA gives an outline of his talk on the different…
Frank Griesinger, MD, PhD from the Pius-Hospital Oldenburg, Oldenburg, Germany discusses the role of p53 mutation in EGFR mutation positive…
David Currow, PhD, MPH, FRACP, FAChPM, FAHMS, GAICD of Flinders University, Adelaide, Australia talks about his poster at the 2016…
Charlotta Pisinger, PhD, MD, MPH of the Rigshospitalet, Copenhagen, Denmark discusses e-cigarettes and their impact on health. She talks about…
Charles Rudin MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY discusses targeted therapies, immunotherapy and their…
Beth Eaby-Sandy MSN, CRNP, OCN, of the Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA explains the different toxicities seen…
Barbara Melosky, MD, FRCPC, of the University of British Columbia, Vancouver, BC discusses how the world of epidermal growth factor…
Ales Ryska, MD, PhD, of the Charles University, Medical Faculty Hospital, Prague, Czech Republic gives an overview of a session…
At ASH 2016, MPN experts from across the nation share their perspective on what the future holds for MPNs, in…
It is an honor and a privilege to be selected to present at the American Society of Hematology Conference. Dr.…
It is an honor and a privilege to be selected to present at the American Society of Hematology Conference. Dr.…
It is an honor and a privilege to be selected to present at the American Society of Hematology Conference. Dr.…
It is an honor and a privilege to be selected to present at the American Society of Hematology Conference. Dr.…
At ASH 2016, experts from across the nation discuss how genetic testing is affecting the evolution of treatment for MPNs.…
We continue to provide informational videos for our Spanish speaking community and welcome Dr. Luis Raez, MD FACP FCCP, Chief…
In this presentation from Lymphoma & Myeloma 2016, Dr. Joseph R. Mikhael discusses the best induction therapy for transplant-eligible myeloma…
In this presentation from Lymphoma & Myeloma 2016, Dr. Philippe Moreau argues that myeloma patients should receive maintenance therapy indefinitely…
In this presentation from Lymphoma & Myeloma 2016, Dr. James R. Berenson argues for no or limited maintenance therapy in…
In this presentation from Lymphoma & Myeloma 2016, Dr. Kenneth C. Anderson discusses new paradigms and therapies in the treatment…
In this presentation from Lymphoma & Myeloma 2016, Dr. Maria-Victoria Mateos discusses how to assess who has smoldering myeloma and…
In this presentation from Lymphoma & Myeloma 2016, Dr. C. Ola Landgren provides an update on new approaches and the…
In this presentation from Lymphoma & Myeloma 2016, Dr. Scott A. Ely elucidates a fresh look at myeloma proliferation. Earn…
In this presentation from Lymphoma & Myeloma 2016, Dr. Raphael Fonseca discusses the challenges in defining an actionable approach to…
In this Key Insights activity, Drs. Corey J. Langer, MD and Joshua Bauml discuss the key take-home points from the…
At ASH 2016, MPN experts from around the nation came together to review current and developing therapies for MPNs. Dr.…
Theodore S. Hong, MD of Massachusetts General Hospital talks about the Promising Results for Folfirinox with Losartan in Locally Advanced…
Theodore S. Hong, MD of Massachusetts General Hospital outlines a Phase II Study of Folfirinox followed my Individualized Radiation Therapy…
Theodore S. Hong, MD of Massachusetts General Hospital outlines how Metformin may increase Overall Survival in Patients with Resectable Pancreatic…
Theodore S. Hong, MD of Massachusetts General Hospital discusses the Secondary Analysis of RTOG 9704 Gemcitabine versus 5-FU in Resectable…
Theodore S. Hong, MD of Massachusetts General Hospital outlines how Novel Agents and Proton Beam Therapy studies may be on…
Theodore S. Hong, MD of Massachusetts General Hospital says that a 2nd Opinion from Surgeon Helpful in the Management of…
John L. Marshall of Lombardi Comprehensive Cancer Institute discusses how the results of the RESORCE Trial will impact treatment for…
John L. Marshall, MD of Lombardi Comprehensive Cancer Center gives his perspective on how to choose molecular tests for treating…
John L. Marshall, MD of Lombardi Comprehensive Cancer Center gives his take on how to integrate genetic mutations, and left…
John L. Marshall MD, of Lombardi Comprehensive Cancer Center discusses how checkpoint inhibitors are being integrated into gastrointestinal cancers at…
John L. Marshall of Lombardi Comprehensive Cancer Center discusses how vaccines can be used to broaden the use of immunotherapies…
Philip Agop Philip, MD, PhD, FRCP of Karmanos Cancer Institute gives his perspective on considerations when treating a newly diagnosed…
Philip Agop Philip, MD, PhD, FRCP of Karmanos Cancer Institute gives his perspective on how to use both TAS-102 and…
Philip Agop Philip, MD, PhD, FRCP of Karmanos Cancer Institute discusses whether or not resected pancreatic cancer patients should be…
Philip Agop Philip, MD, PhD, FRCP of Karmanos Cancer Institute gives his take on choosing molecular tests for treatment for…
Philip Agop Philip, MD, PhD, FRCP of Karmanos Cancer Institute discusses how healthcare professionals are integrating immunotherapy in existing treatment…
Stevin Lin, MD, PhD of MD Anderson Cancer Center highlights how Proton Therapy May Have Benefits to Immunotherapy Treatments from…
Stevin Lin, MD, PhD of MD Anderson Cancer Center discusses how using Proton therapy can lower Lymphopenia in esophageal cancer…
Stevin Lin, MD, PhD of MD Anderson Cancer Center outlines the next steps for research and clinical trials associated to…
Stevin Lin, MD, PhD of MD Anderson discusses the costs of Proton Therapy versus the cost of IMRT and 3d…
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses how the 80405 study in CRC…
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center gives his take on ordering which molecular…
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center gives his perspective on how to use…
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center talks of how he identifies subgroups of…
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses the date of the RESORCE Trial…
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses how healthcare professionals are integrating immunotherapy…
Alan P. Venook MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses integrating immunotherapy into existing treatment regimens…
Alan P. Venook, M.D., FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses how to integrate immunotherapy into existing…
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses how checkpoint inhibitors will be used in unresectable HCC treatment…
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses how targeted therapies seem to work better for patients with…
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses regorafenib in clinical practice at the 2017 Gastrointestinal Cancers Symposium…
Thomas A. Abrams, MD of Dana Farber Cancer Institute gives an overview of the results of the RESORCE trial, that…
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses new agents for the treatment of advanced HCC at the…
Arturo Loaisa-Bonilla, MD of the Abramson Cancer Center of the University of Pennsylvania discusses Gallium 68 versus Low Volume PRRT…
Arturo Loaisa-Bonilla, MD of the Abramson Cancer Center of the University of Pennsylvania states that Gallium 68 should be Used…
Arturo Loaisa-Bonilla, MD of the Abramson Cancer Center of the University of Pennsylvania discusses how Gallium 68 Provides Much More…
Arturo Loaisa-Bonilla, MD of the Abramson Cancer Center answers the question Where to Put PRRT in the Treatment Paradigm at…
Arturo Loaisa-Bonilla, MD of Abramson Cancer Center discusses the relationship between Theranostics and Sumaratin Receptors in Neuroendocrine Cells at ASCO…
As part of our ASH 2016 coverage, Dr. John Mascarenhas, from Mount Sinai School of Medicine, joined Patient Power to…
Ian Chau, MD, FRCP of Royal Marsden Hospital discusses how Nivolumab Shows Significant Overall Survival Benefit in Metastatic Gastric Cancer…
Ian Chau, MD, FRCP of Royal Marsden Hospital discusses the Potential Scenarios for Ramucirumab plus Pembrolizumab at ASCO GI 2017
Arturo Loaisa-Bonilla, MD of Abramson Cancer Center discusses how Gallium 68 Scan has now Become Standard for Staging Neuroendocrine Tumors…
Davendra Sohal, MD of Cleveland Clinic outlines the Pancreatic Cancer Trends for 2017 from ASCO GI 2017
Davendra Sohal, MD of Cleveland Clinic discusses that Improvement in Systemic Therapies are Needed in in Pancreatic Cancer from ASCO…
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael…
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael…
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael…
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael…
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael…
Davendra Sohal, MD of Cleveland Clinic presents the Results from Internal Expedience Borderline Resectable Pancreas Cancer at ASCO GI 2017
David Ilson, MD of Memorial Sloan Kettering outlines Potential Practicing Changing Data from ASCO GI 2017
David Ilson, MD of Memorial Sloan Kettering gives an in depth overview of the data presented at ASCO GI 2017
Howard S. Hochster, MD of Yale Cancer Center discusses how healthcare professionals will be integrating immunotherapy into existing treatment regimens…
Howard S. Hochster, MD of Yale Cancer Center discusses the outcomes of the randomized phase 2 study in BRAF-mutated patients…
David Ilson, MD of Memorial Sloan Kettering describes the Advantages of Induction Chemotherapy in Esophageal Cancer at ASCO GI 2017
Howard S. Hochster, MD of Yale Cancer Center discusses how genetic profiling has changed the treatment approach for patients with…
Cynthia Sears, MD of Johns Hopkins sees a promising link to Microbiome Study and MSI Colorectal Cancer Immunotherapy. Interviewed at…
Howard S. Hochster, MD of Yale Cancer Center discusses how to use both TAS-102 and Regorafenib in patients with metastatic…
Davendra Sohal, MD of Cleveland Clinic answers the question Will SWOG S1505 Impact Treatment of Pancreatic Cancer at ASCO GI…
Howard S. Hochster, MD of Yale Cancer Center discusses the difference between Regorafenib, 5FU, and TAS-102 at the 2017 Gastrointestinal…
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering gives his view on checkpoint inhibitors and their incorporation into treatment for…
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center discusses his view on reliably identifying subgroups of patients for…
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center discusses his thoughts on whether or not physicians will start…
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center gives his take on the outcomes of the RESORCE trial,…
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center gives his take on integration of new agents for advanced…
SCCA’s Dr. Ajay Gopal discusses treatment options in lymphoma and chronic lymphocitic leukemia (CLL), as well as the strength of…
Nevena Damjanov, MD of University of Pennsylvania talks about how checkpoint inhibitors will be incorporated into unresectable HCC treatment at…
Nevena Damjanov, MD of University of Pennsylvania discusses how healthcare professionals can reliably identify subgroups of patients for targeted therapies…
Nevena Damjanov, MD of University of Pennsylvania discusses how regorafenib will be incorporated into clinical practice at 2017 Gastrointestinal Cancers…
Nevena Damjanov, MD of University of Pennsylvania gives an overview of the outcomes of the RESORCE Trial that were presented…
Nevena Damjanov, MD of University of Pennsylvania discusses how new agents being studied for advanced HCC will be integrated into…
David Ilson, MD of Memoral Sloan Kettering Cancer Center discusses data released at ASCO GI 2017. A total of 198…
Cynthia Sears, MD of John Hopkins University School of Medicine highlights there is Accumulating evidence that the microbiome may play…
A cancer research team led by Dean Tang, PhD, found a specific miRNA (or microRNA) molecule that stunts prostate cancer…
Michael Soulen, MD of Hospital of the University of Pennsylvania gives an update on the RETNET Trial or the Randomized…
Davendra Sohal, MD of Cleveland Clinic outlines the SWOG S1505 Clinical Trial Requirements at ASCO GI 2017
Johanna Bendell, MD of Sarah Cannon Research Institute discusses the Proprietary Neoantigen Identification Technology Platform at the 2017 Gastrointestinal Cancers…
Johanna Bendell, MD of Sarah Cannon Research Institute discusses the RESORCE Trial and how its data can change treatment for…
Johanna Bendell, MD of Sarah Cannon Research Institute discusses the challenges she’s faced in treating pancreatic cancer at the 2017…
Johanna Bendell, MD of Sarah Cannon Research Institute discusses the upcoming trial and drug development in pancreatic and gastrointestinal cancers…
Johanna Bendell, MD of Sarah Cannon Research Institute discusses the phase 3 study in advanced gastric or GE junction cancer…
Jeffrey A. Meyerhardt, MD of Dana Farber Cancer Institute discusses the DFCI wellness study and how it states that CRC…
Jeffrey A. Meyerhardt, MD of Dana Farber Cancer Institute gives an overview of the outcomes of the randomized phase 2…
Jeffrey A. Meyerhardt, MD of Dana Farber Cancer Institute discusses the four consensus molecular subtypes and how they help with…
Jeffrey A. Meyerhardt, MD of Dana Farber Cancer Institute discusses molecular testing in determining treatment approach for patients with colorectal…
Jeffrey A. Meyerhardt, MD of Dana Farber Cancer Institute discusses how immunotherapy is being integrated into existing treatments for patients…
Edith P. Mitchell, MD, FACP of Sidney Kimmel Cancer Center discusses how new classifications of gastric cancer subtypes, based on…
Edith P. Mitchell, MD, FACP of Sidney Kimmel Cancer Center gives an overview of the progress to date of the…
Edith P. Mitchell, MD, FACP of Sidney Kimmel Cancer Center discusses how organoids are being used in cancer biology research…
Edith P. Mitchell, MD, FACP of Sidney Kimmel Cancer Center discusses how the Blue Ribbon Panel may help with the…
Edith P. Mitchell, MD, FACP of Sidney Kimmel Cancer Center discusses immunotherapy in colorectal cancer at the 2017 Gastrointestinal Cancers…
David Ilson, MD of Memorial Sloan Kettering gives an overview of the CALGB 80803 PET Assessment to Optimize Neoadjuvant Chemotherapy…
Cynthia Sears, MD of Johns Hopkins University discusses her lecture entitled Microbes, Microbiota, and Colon Cancer from ASCO GI 2017
Alan P. Venook, MD of the University of California San Francisco describes which colorectal patients will benefit the most from…
Ian Chau, MD, FRCP of Royal Marsden Hospital discusses the results of a Phase I Study of Ramucirumab + Pembrolizumab…
Theodore S. Hong, MD of Massachusetts General Hospital discusses the management of recurrent rectal cancer at ASCO Gi 2017
Steven Lin, MD, PhD from MD Anderson Cancer Center discusses Advances in Radiation Therapy: IMRT and Proton Therapy for Esophageal…